Gout (Hyperuricemia) News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Nippon Chemiphar Announces Progress on Its Hyperuricemia/Gout Projects - TASS



Nippon Chemiphar Announces Progress on Its Hyperuricemia/Gout Projects 
TASS
TOKYO, Nov. 29, 2017 /PRNewswire/. Nippon Chemiphar Co., Ltd. has announced that the Phase-1 clinical trial of NC-2500, a novel xanthine oxidoreductase (XOR) inhibitor, was completed, indicating that it has potential to reduce the risk of gout flare ...

and more » 


Febuxostat Lowers Blood Pressure in Patients With Hyperuricemia and Hypertension - Rheumatology Advisor



Rheumatology Advisor
 
Febuxostat Lowers Blood Pressure in Patients With Hyperuricemia and Hypertension 
Rheumatology Advisor
Use of the xanthine oxidase inhibitor febuxostat may reduce 24-hour ambulatory systolic blood pressure (SBP) in patients with hypertension, hyperuricemia, and normal renal function, according to the results of a recent phase 2 randomized placebo ...

 


Nippon Chemiphar Announces Progress on Its Hyperuricemia/Gout Projects; NC-2500 Shows Favorable Profile to ... - PharmiWeb.com (press release)



Nippon Chemiphar Announces Progress on Its Hyperuricemia/Gout Projects; NC-2500 Shows Favorable Profile to ... 
PharmiWeb.com (press release)
TOKYO, Nov. 29, 2017 /PRNewswire/ -- Nippon Chemiphar Co., Ltd. has announced that the Phase-1 clinical trial of NC-2500, a novel xanthine oxidoreductase (XOR) inhibitor, was completed, indicating that it has potential to reduce the risk of gout flare ...

 


FDA Issues Safety Alert for Gout Medication - Renal and Urology News



Renal and Urology News
 
FDA Issues Safety Alert for Gout Medication 
Renal and Urology News
In a safety announcement released Wednesday, the FDA warns of an increased risk for heart-related death with febuxostat (Uloric) compared with allopurinol for the treatment of gout. The new findings are preliminary results from a safety study conducted ...

and more » 


Gout: Causes, Signs, Symptoms & Prevention - Times of India



Times of India
 
Gout: Causes, Signs, Symptoms & Prevention 
Times of India
The most common point of Gout is the big toe. When Gout is mild, infrequent and less complicated, it can be treated with diet and lifestyle changes. Gout is associated with obesity and significant weight loss can dramatically improve the management of ...

 


Metoprolol Elevates Serum Uric Acid and Gout Risk in African Americans - Rheumatology Advisor



Rheumatology Advisor
 
Metoprolol Elevates Serum Uric Acid and Gout Risk in African Americans 
Rheumatology Advisor
These findings were recently reported in the American Journal of Hypertension. There is considerable comorbidity among hyperuricemia, hypertension, and CKD. As little guidance exists for clinicians when choosing antihypertensive agents in patients with ...

 


Lead Contamination in Bone Broth Too? - Care2.com



Care2.com
 
Lead Contamination in Bone Broth Too? 
Care2.com
However, we now know that ?[b]lood lead levels in the range currently considered acceptable are associated with increased prevalence of gout and hyperuricemia? (elevated levels of uric acid in the blood). According to the Centers for Disease Control ...

 


Ironwood Pharmaceuticals, Inc. (IRWD) CEO Sells $1714683.60 in Stock - The Ledger Gazette



The Ledger Gazette
 
Ironwood Pharmaceuticals, Inc. (IRWD) CEO Sells $1714683.60 in Stock 
The Ledger Gazette
Ironwood Pharmaceuticals logo Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) CEO Peter M. Hecht sold 113,405 shares of Ironwood Pharmaceuticals stock in a transaction dated Thursday, December 7th. The stock was sold at an average price of $15.12, for a ...
The Fmr LLC Has $330.60 Million Position in Ironwood Pharmaceuticals, Inc. (IRWD) BangaloreWeekly
Julie Mchugh Sells 1,500 Shares of Ironwood Pharmaceuticals, Inc ... StockNewsTimes
Ironwood Pharmaceuticals (IRWD) Now Covered by Analysts at Credit Suisse Group Dispatch Tribunal
Key Gazette  -The Lincolnian Online  -Zacks Investment Research  -SEC.gov 
all 78 news articles » 


FDA Approves First Fixed-Dose Combo Treatment for Hyperuricemia in Gout - Genetic Engineering & Biotechnology News



Rheumatology Advisor
 
FDA Approves First Fixed-Dose Combo Treatment for Hyperuricemia in Gout 
Genetic Engineering & Biotechnology News
The FDA has approved the first fixed-dose combination treatment designed to address in a single pill both causes of hyperuricemia in gout?overproduction and underexcretion of serum uric acid. Ironwood Pharmaceuticals will market DuzalloŽ (lesinurad ...
FDA Approves Duzallo for Hyperuricemia Associated With Uncontrolled Gout Rheumatology Advisor
(lesinurad and allopurinol) for the Treatment of Hyperuricemia in Patients with Uncontrolled Gout Business Wire (press release)
FDA Clears First Fixed-Dose Combination Treatment for Gout Medscape
Pharmacy Times  -P&T Community  -Boston Business Journal 
all 30 news articles » 


CymaBay Therapeutics Strengthens Management Team with Appointment of Paul Quinlan as General Counsel - Markets Insider



CymaBay Therapeutics Strengthens Management Team with Appointment of Paul Quinlan as General Counsel 
Markets Insider
NEWARK, Calif., Dec. 04, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that Paul ...

and more »